Microsoft word - references for treatment to goal with statins assessing patients cholesterol levels and effectiveness of stati

Treatment to Goal with Statins— Assessing Patients’ Cholesterol Levels The Ohio Family Physician, Spring 2011 1. Blauw, S.J., Murphy, M.B., Bollen, E.L., Buckley, B.M., Cobbe, S.M., Ford, I., Gaw, A., Hyland, J.M., Kamper, A.M., Macfarlane, P.W., Meinders, A.E., Norrie, J., Packard, C.J., Perry, I.J., Stott, D.J., Sweeney, B.J., Twomey, C., Westendorp, R.G. (2002). Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet, 360, 1623-1630. 2. Brown, W.V., Bays, H.E., Hassman, D.R., McKenney, J., Chitra, R., Hutchinson, H., Miller, E. (2002). Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. American Heart Journal, 144, 1036-1043. 3. Cannon, C.P., Braunwald, E., McCabe, C.H., Rader, D.J., Rouleau, J.L., Belder, R., Joyal, S.V., Hill, K.A., Pfeffer, M.A., Skene, A.M. (2004). Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine, 350, 1495-1504. 4. Davidson, M., Ma, P., Stein, E.A., Gotto, Jr., A.M., Raza, A., Chitra, R., Hutchinson, H. (2002). Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. American Journal of Cardiology, 89, 268-275. 5. Grundy, S.M., Cleeman, J.I., Merz, C.N.B., Brewer, Jr., H.B., Clark, L.T., Hunningshake, D.B., Pasternak, R.C., Smith, Jr., S.C., Stone, N.J. (2004) Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation, 110, 227-239. 6. Heart Protection Study Collaborative Group. (2002). Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet, 360, 7-22. 7. Jones, P.H., Davidson, M.H., Stein, E.A., Bays, H.E., McKenney, J.M., Miller, El, Cain, V.A., Blasetto, J.W. (2003). Comparison of the Efficacy and Safety of Rosuvastatin versus Atorvastatin, Simvastatin, and Pravastatin across Doses (STELLAR Trial). American Journal of Cardiology, 92, 152-160. 8. Olsson, A.G., Istad, H., Luurila, O., Ose, L., Stender, S., Tuomilehto, J., Wiklund, O., Southworth, H., Pears, J., Wilpshaar, J.W. (2002). Effects of Rosuvastatin and Atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. American Heart Journal, 144, 1044-1051. 9. Paoletti, R., Fahmy, M., Mahla, G., Mizan, J., Southworth, H. (2001). Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolemic patients: a randomized, double-blind study. Journal of Cardiovascular Risk, 8, 383-390. 10. Sever, P.S., Dahlof, B., Poulter, N.R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S.E., Kristinsson, A., McInnes, G.T. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations. (2003). Lancet, 361, 1149-1158.


Uro contemporanea_capa e 2 capa.indd

uro-rESumoS brasil silva neto Doutor em Medicina: Ciências Cirúrgicas Universidade Federal do Rio Grande do Sul Serviço de Urologia Hospital de Clínicas de Porto Alegre U. S. Surveillance, Epidemiology, and End Results Milton berger Professor Adjunto de Urologia da Universidade Federal do Rio Grande do Sul im C. HU  iangmei gU  tUart r. lipsitz Jama. 2009; 302(14):1557-1564

Copyright © 2010-2014 Medical Articles